Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: Clustered mutations in three functional genes, E2, NS2, and NS5a

Journal of Virology

Volumn 82, Issue 19, 2008, Pages 9417-9424

  Xu, Zekuan ^a,c   Fan, Xiaofeng ^a,b   Xu, Yanjuan ^a   Di Bisceglie, Adrian M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

AMPLICON; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CONSENSUS SEQUENCE; CONTROLLED STUDY; E2 GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NS2 GENE; NS5A GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; VIRUS GENE; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; GENOME, VIRAL; HEPACIVIRUS; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 52649090810     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00896-08     Document Type: Article

References (34)

1. Barbour, J. D., T. Wrin, R. M. Grant, J. N. Martin, M. R. Segal, C. J. Petropoulos, and S. G. Deeks. 2002. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:11104-11112.
2. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
3. Bonhoeffer, S., C. Chappey, N. T. Parkin, J. M. Whitcomb, and C. J. Petropoulos. 2004. Evidence for positive epistasis in HIV-1. Science 306:1547-1550.
4. Chambers, T. J., X. Fan, D. A. Droll, E. Hembrador, T. Slater, M. W. Nickells, L. B. Dustin, and A. M. Di Bisceglie. 2005. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol. 79:3071-3083.
5. Charpentier, C., D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78:4234-4247.
6. Di Bisceglie, A. M. 1998. Hepatitis C. Lancet 351:351-355.
7. Domingo, E., and J. Gomez. 2007. Quasispecies and its impact on viral hepatitis. Virus Res. 127:131-150.
8. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, N. Izumi, F. Maruino, and C. Sato. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis-C virus 1b-sensitivity to interferon is conferred by amino-acid substitutions in the NS5a region. J. Clin. Investig. 96:224-230.
9. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N. Engl. J. Med. 334:77-81.
10. Fan, X., A. C. Lyra, D. Tan, Y. Xu, and A. M. Di Bisceglie. 2001. Differential amplication of hypervariable region 1 of hepatitis C virus by partially mismatched primers. Biochem. Biophy. Res. Commun. 284:694-697.
11. Fan, X., H. Solomon, J. E. Poulos, B. A. Neuschwander-Tetri, and A. M. Di Bisceglie. 1999. Comparison of genetic heterogeneity of hepatitis C viral RNA in liver tissue and serum. Am. J. Gastroenterol. 94:1347-1354.
12. Fan, X., Y. Xu, and A. M. Di Biceglie. 2006. Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. Biochem. Biophys. Res. Commun. 346:1163-1172.
13. Feld, J. J., and J. H. Hoofnagle. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
14. Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
15. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
16. Higgins, D. G., and P. M. Sharp. 1988. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 73:237-244.
17. Kalinina, O., H. Norder, S. Mukomolov, and L. O. Magnius. 2002. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 76:4034-4043.
18. Kimura, M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:111-120.
19. Kuiken, C., M. Mizokami, G. Deleage, K. Yusim, F. Penin, T. Shin-I, C. Charavay, N. Tao, D. Crisan, D. Grando, A. Dalwani, C. Geourjon, A. Agrawal, and C. Combet. 2006. Hepatitis C databases, principles and utility to researchers. Hepatology 43:1157-1165.
20. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5:150-163.
21. Legrand-Abravanel, F., J. Claudinon, F. Nicot, M. Dubois, S. Chapuy-Regaud, K. Sandres-Saune, C. Pasquier, and J. Izopet. 2007. New natural intergenotypic (2/5) recombinant of hepatitis C virus. J. Virol. 81:4357-4362.
22. Moreno, M. P., D. Casane, L. Lopez, and J. Cristina. 2006. Evidence of recombination in quasispecies populations of a hepatitis C virus patient undergoing anti-viral therapy. Virol. J. 3:87.
23. Negro, F., M. Baldi, A. Mondardini, G. Leandro, M. Chaneac, P. Manzini, M. L. Abate, G. Verme, and F. Bonino. 1994. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 107:479-485.
24. Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. B. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
25. Okada, S., Y. Akahane, H. Suzuki, H. Okamoto, and S. Mishiro, S. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
26. Roffi, L., G. C. Mels, G. Antonelli, G. Bellati, F. Panizzuti, A. Piperno, M. Pozzi, D. Ravizza, G. Angeli, F. Dianzani, and G. Mancia. 1995. Break-through during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21:645-649.
27. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
28. Shapiro, B., A. Rambaut, O. G. Pybus, and E. C. Holmes. 2006. A phylogenetic method for detecting positive epistasis in gene sequences and its application to RNA virus evolution. Mol. Biol. Evol. 23:1724-1730.
29. Taylor, D. R., S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110.
30. Torres-Puente, M., M. A. Bracho, N. Jimenez, I. Garcia-Robles, A. Moya, and F. Gonzalez-Candelas. 2003. Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J. Gen. Virol. 84:2343-2350.
31. Wohnsland, A., W. P. Hofmann, and C. Sarrazin. 2007. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20:23-38.
32. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.
33. Young, K. C., K. L. Lindsay, K. J. Lee, W. C. Liu, J. W. He, S. L. Milstein, and M. M. Lai. 2003. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38:869-878.
34. Zhou, D., X. Fan, D. Tan, Y. Xu, J. E. Tavis, and A. M. Di Bisceglie. 2007. Separation of near full-length hepatitis C virus quasispecies variants from a complex population. J. Virol. Methods 141:220-224.